Stock events for Lantheus Holdings, Inc. (LNTH)
Lantheus reported strong Q4 2025 financial results but provided cautious full-year 2026 guidance. The company received FDA approval for PYLARIFY TruVu and tentative approval for Lutetium Lu 177 Dotatate. Analyst ratings were upgraded to "strong-buy" by Wall Street Zen. PYLARIFY sales experienced a decline due to pricing pressure and changes in Medicare coverage. Lantheus completed the acquisition of Life Molecular Imaging and divested its legacy SPECT business. The company repurchased $100 million of common stock in Q3 and Q4 2025.
Demand Seasonality affecting Lantheus Holdings, Inc.’s stock price
No specific demand seasonality for Lantheus Holdings, Inc.'s products and services has been explicitly identified. The company's focus on addressing growing demand for products like PYLARIFY suggests a generally consistent, rather than seasonal, demand for its diagnostic tools.
Overview of Lantheus Holdings, Inc.’s business
Lantheus Holdings, Inc. is a radiopharmaceutical company focused on improving patient outcomes by enabling clinicians to find, fight, and follow diseases. The company develops, manufactures, and commercializes diagnostic and therapeutic products, primarily radiopharmaceuticals and medical imaging agents. Its product portfolio includes PYLARIFY, a diagnostic agent for prostate cancer imaging; DEFINITY, an ultrasound enhancing agent; TechneLite, a generator for essential nuclear material; and Neuraceq, an amyloid PET imaging agent for Alzheimer's disease. Lantheus also has a pipeline including PNT2002, a therapeutic radiopharmaceutical for metastatic castration-resistant prostate cancer; PNT2003, a radioequivalent to LUTATHERA; NAV-4694, a B amyloid PET imaging agent; MK-6240, an F 18-labeled tau-targeted PET imaging agent; and LNTH-2501, a diagnostic kit for PET imaging of SSTR+ NETs.
LNTH’s Geographic footprint
Lantheus is headquartered in Massachusetts, USA, with additional offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom. The company operates through U.S. and International geographical segments. Its products are distributed directly in the U.S. and Canada, and through third-party relationships in Europe, Australia, Asia-Pacific, Central America, and South America.
LNTH Corporate Image Assessment
Lantheus's brand reputation has been shaped by its strategic transformation and product advancements. FDA approvals and strategic acquisitions have positively impacted its reputation, demonstrating a commitment to expanding patient access and addressing unmet medical needs. Challenges related to PYLARIFY's pricing and volume, coupled with cautious 2026 guidance, have introduced some investor apprehension and led to stock price declines.
Ownership
Lantheus Holdings, Inc. is predominantly owned by institutional investors, including BlackRock, Inc., Vanguard Group Inc., and Janus Henderson Group Plc. Significant individual insider owners include Sriram Venkataraman, Avista Capital Partners GP LLC, and David F. Burgstahler.
